62
Participants
Start Date
August 30, 2021
Primary Completion Date
July 3, 2023
Study Completion Date
July 3, 2023
Amivantamab
Amivantamab will be administered intravenously.
National Cancer Center Hospital, Chūōku
National Cancer Center Hospital East, Kashiwa
Saitama Cancer center, Kitaadachi-gun
Niigata Cancer Center Hospital, Niigata
Hokkaido University Hospital, Sapporo
Tohoku University Hospital, Sendai
Osaka University Hospital, Suita-shi
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo
The Cancer Institute Hospital of JFCR, Tokyo
Yokohama City University Medical Center, Yokohama
Lead Sponsor
Janssen Pharmaceutical K.K.
INDUSTRY